Anti-COMT Antibody

Developed in rabbit as a polyclonal reagent, this unconjugated primary antibody targets catechol-O-methyltransferase (COMT), the methyltransferase that inactivates catecholamine neurotransmitters and catechol estrogens through S-adenosylmethionine-dependent O-methylation. The Antibodies.com preparation is validated for Western blot and immunohistochemistry workflows and shows cross-reactivity with Human, Mouse, and Rat COMT, supporting studies of dopaminergic signaling, catecholamine turnover, estrogen metabolism, and neurological disease models. Supplied as 100 µl of liquid at 1 mg/ml in PBS with 0.1% sodium azide and 50% glycerol acting as a cryoprotective vehicle, the antibody is aliquoted into a single-use vial that dilutes readily into standard blocking and incubation buffers. Investigators probing COMT polymorphisms tied to psychiatric phenotypes, pain perception, and estrogen-driven cancers use this reagent to localize MB-COMT and S-COMT isoform expression across tissues, cultured cells, and tissue microarrays.